Moreover, the pharmacological inhibition of c-KIT [44,45], the antibody-based inhibition of OX40L [46], or genetic ablation could be a potential future strategy to improve the anti-tumor activity of NK cells in response to therapeutic treatment with monoclonal antibodies, such as RTX. This evidence concerns the gene TNFSF4 and neoplasm.